These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24439671)

  • 21. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
    Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
    Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
    Innocenti F; Ratain MJ
    Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).
    Chen S; Yueh MF; Bigo C; Barbier O; Wang K; Karin M; Nguyen N; Tukey RH
    Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19143-8. PubMed ID: 24191041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
    Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
    Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
    Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
    Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
    Xu G; Zhang W; Ma MK; McLeod HL
    Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
    Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
    Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
    Onoue M; Inui K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1080-5. PubMed ID: 18633245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.
    Okumura M; Iwakiri T; Takagi A; Hirabara Y; Kawano Y; Arimori K
    Biochem Pharmacol; 2011 Dec; 82(11):1720-30. PubMed ID: 21840303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
    Hasegawa Y; Ando Y; Shimokata K
    Expert Rev Mol Diagn; 2006 Jul; 6(4):527-33. PubMed ID: 16824027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment with CPT-11 based on the UGT1A1 genetic polymorphism].
    Nishi T; Komaki T; Hamamoto Y
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():545-9. PubMed ID: 22214020
    [No Abstract]   [Full Text] [Related]  

  • 34. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
    Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.
    Tanimoto K; Kaneyasu M; Shimokuni T; Hiyama K; Nishiyama M
    Pharmacogenet Genomics; 2007 Jan; 17(1):1-10. PubMed ID: 17264798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Importance and practice of UGT1A1 polymorphisms].
    Hazama S; Oka M
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():351-4. PubMed ID: 22213983
    [No Abstract]   [Full Text] [Related]  

  • 38. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
    Ando Y; Fujita K; Sasaki Y; Hasegawa Y
    Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
    Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.